金域医学
(603882)
| 流通市值：145.26亿 | | | 总市值：146.25亿 |
| 流通股本：4.60亿 | | | 总股本：4.63亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,996,929,115.16 | 1,466,504,705.88 | 7,189,544,739.91 | 5,618,852,446.76 |
| 营业收入 | 2,996,929,115.16 | 1,466,504,705.88 | 7,189,544,739.91 | 5,618,852,446.76 |
| 二、营业总成本 | 2,850,900,501.38 | 1,411,296,745.89 | 6,748,751,288.99 | 5,117,588,587.38 |
| 营业成本 | 1,979,982,984.96 | 978,934,517.43 | 4,806,525,640.59 | 3,643,595,996.75 |
| 税金及附加 | 6,687,137.94 | 3,260,434.76 | 15,907,999.08 | 11,588,847.08 |
| 销售费用 | 420,766,367.51 | 213,460,190.85 | 930,618,346.71 | 677,896,671.99 |
| 管理费用 | 285,478,221.51 | 140,587,531.11 | 598,004,111.67 | 483,109,316.58 |
| 研发费用 | 160,713,609.9 | 77,105,975.66 | 400,469,423.29 | 302,366,808.51 |
| 财务费用 | -2,727,820.44 | -2,051,903.92 | -2,774,232.35 | -969,053.53 |
| 其中:利息费用 | 8,008,647.7 | 4,153,747.33 | 18,428,466.69 | 14,154,937.35 |
| 其中:利息收入 | 11,860,511.92 | 6,851,875.84 | 23,476,697.35 | 16,887,190.64 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | -30,798,817.27 | - |
| 加:投资收益 | 2,008,308.27 | 638,803.17 | -37,083,018.3 | -5,122,643.98 |
| 资产处置收益 | 2,441,961.14 | 2,326,660.53 | 6,364,363.75 | 4,659,777.47 |
| 资产减值损失(新) | 125,413.97 | -300,124.76 | -72,623,272.86 | 40,419.96 |
| 信用减值损失(新) | -272,474,717.4 | -105,894,664.69 | -619,477,916.88 | -420,559,824.32 |
| 其他收益 | 15,772,152.19 | 11,799,078.63 | 39,581,201.81 | 29,929,734.86 |
| 四、营业利润 | -106,098,268.05 | -36,222,287.13 | -273,244,008.83 | 110,211,323.37 |
| 加:营业外收入 | 739,041.21 | 525,135.48 | 4,587,869.36 | 1,789,837.13 |
| 减:营业外支出 | 4,248,901.23 | 1,617,208.36 | 169,990,378.08 | 16,060,040.36 |
| 五、利润总额 | -109,608,128.07 | -37,314,360.01 | -438,646,517.55 | 95,941,120.14 |
| 减:所得税费用 | -12,739,987.55 | -2,588,381.83 | -23,942,816.63 | 12,073,258.49 |
| 六、净利润 | -96,868,140.52 | -34,725,978.18 | -414,703,700.92 | 83,867,861.65 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -96,868,140.52 | -34,725,978.18 | -414,703,700.92 | 83,867,861.65 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -84,806,829.28 | -27,785,254.88 | -381,241,138.69 | 93,838,992.07 |
| 少数股东损益 | -12,061,311.24 | -6,940,723.3 | -33,462,562.23 | -9,971,130.42 |
| 扣除非经常损益后的净利润 | -97,962,797.01 | -38,700,504.33 | -237,977,799.7 | 78,011,214.81 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.18 | -0.06 | -0.82 | 0.2 |
| (二)稀释每股收益 | -0.18 | -0.06 | -0.82 | 0.2 |
| 八、其他综合收益 | -8,271,686.13 | -1,934,363.99 | 10,627,301.67 | -3,044,204.15 |
| 归属于母公司股东的其他综合收益 | -8,271,686.13 | -1,934,363.99 | 10,627,301.67 | -3,044,204.15 |
| 九、综合收益总额 | -105,139,826.65 | -36,660,342.17 | -404,076,399.25 | 80,823,657.5 |
| 归属于母公司股东的综合收益总额 | -93,078,515.41 | -29,719,618.87 | -370,613,837.02 | 90,794,787.92 |
| 归属于少数股东的综合收益总额 | -12,061,311.24 | -6,940,723.3 | -33,462,562.23 | -9,971,130.42 |
| 公告日期 | 2025-08-23 | 2025-04-26 | 2025-04-26 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |